Eli Lilly and Company's staggering $27 billion investment in U.S. manufacturing facilities raises eyebrows (and maybe a few hackles!) amidst ongoing tariff talks. This bold move signals a potential shift in Big Pharma's strategy, prompting a closer look at the interplay of politics, economics, and corporate maneuvering. Is this a preemptive strike against potential tariffs, a savvy long-term..
